Skip to main content
logo
Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
6.76
-0.18 (-2.59%)
Oct 12, 2026, 3:14 PM EDT - Market open

Artiva Biotherapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--0.2533.494.932
Revenue Growth
---99.25%579.21%146.30%-
Gross Profit
--0.2533.494.932
Operating Income
-96.15-89.81-67.28-30.67-59.83-53.27
Net Income
-90.82-83.87-65.37-28.72-58.79-71.83
Earnings Per Share
-3.21-3.43-5.81-35.78-76.67-104.73
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
349.39108.01185.4376.97102.53160.92
Total Debt
9.8510.9414.3516.9119.451.74
Net Cash (Debt)
339.5597.07171.0760.0683.08159.18
Net Cash Growth
162.93%-43.26%184.84%-27.71%-47.81%582.42%
Net Cash Per Share
12.003.9715.1974.82108.36232.10

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-75.23-76.75-55.03-47.43-50.83-15.3
Capital Expenditures
-1.68-2.59-0.64-3.26-6.3-1.72
Free Cash Flow
-76.91-79.34-55.67-50.69-57.13-17.03
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
--100.00%100.00%100.00%100.00%
Operating Margin
---26805.58%-91.58%-1213.32%-2660.94%
Pretax Margin
---26045.02%-85.54%-1191.14%-3587.66%
Profit Margin
---26045.02%-85.75%-1192.21%-3587.66%
FCF Margin
---22180.88%-151.34%-1158.55%-850.55%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
--975.44---